Biotech
Gene editing, synthetic biology, and diagnostics.
Reason No topic weight computed yet.
Articles
20-
MGH Mobile Vascular Clinic Cuts Limb Loss Risk for Homeless Patients
Homeless patients lose limbs at dramatically higher rates than housed patients — not because treatment doesn't exist, but because they never reach it. Massachusetts General Hospital built the clinic around that gap instead of waiting for patients to close it themselves.
Reality 65Hype 35 -
Boehringer's Obesity Drug Stumbles on Weight Loss Despite Liver Win
Boehringer Ingelheim's obesity contender looks good on liver fat — the metric that matters less in a market where GLP-1s are setting the weight-loss bar. New data suggests it may not clear that bar.
Reality 55Hype 25 -
Male Puberty Timing Linked to Long-Term Health Risks, Research Gap Exposed
While early puberty in girls has been studied for decades, the male equivalent is a near-blank page — and that gap may be quietly shaping men's long-term disease risk.
Reality 55Hype 25 -
Iron-Enhanced Biochar Uses Soil Chemistry to Destroy Antibiotic Residues
Antibiotic-contaminated farmland may have a self-cleaning fix — and it runs on chemistry already present in the soil. A new iron-modified biochar doesn't just adsorb pollutants; it oxidatively destroys them using the soil's own oxygen and iron redox cycles.
Reality 65Hype 35 -
AI Is Now Fighting AI Over Your Medical Bills
Hospitals are deploying AI to pre-empt insurer AI that denies claims — and the collateral damage lands on patients. When billing software becomes a clinical variable, the arms race has already escaped the finance department.
Reality 65Hype 45 -
XPRIZE Healthspan Director Separates Longevity Science from Snake Oil
The woman running the world's largest longevity competition is calling out "purely scammy" treatments — and that candor from inside the hype machine is worth paying attention to.
Reality 72Hype 35 -
GSK Hepatitis B Drug Achieves Functional Cure in 20% of Patients
Current hepatitis B treatments almost never cure anyone — GSK's experimental drug just hit a functional cure rate of roughly 1 in 5, a number the field hasn't come close to before.
Reality 62Hype 58 -
Revolution Medicines Cracks KRAS in Pancreatic Cancer at ASCO
For decades, KRAS — the mutation driving most pancreatic cancers — was considered undruggable. Revolution Medicines just reported practice-changing results suggesting that era is over.
Reality 62Hype 58 -
Pharma's "Innovation" Label Is a Monopoly Extension Tool
The word "innovation" is doing a lot of legal heavy lifting in pharma — and almost none of the scientific kind. A new book argues the industry has systematically weaponized the term to justify patent evergreening that has nothing to do with therapeutic progress.
Reality 72Hype 45 -
Lilly's In Vivo Gene Editor Cuts Cholesterol 62% in Early Trial
A single dose of a gene-editing therapy slashed LDL cholesterol by 62% in a human trial — potentially making statins look like a daily inconvenience rather than a lifelong necessity.
Reality 72Hype 58 -
A Medical AI Skeptic Concedes Ground on Administrative Intake
When a self-declared AI skeptic in medicine says "here's where it works," that's worth more than a hundred vendor press releases. The concession: check-in and intake are low-stakes enough for AI to add real value without real danger.
Reality 72Hype 25 -
Parabilis Medicines Files for IPO One Day After Regeneron Deal
Parabilis Medicines timed its IPO announcement with surgical precision — dropping it the day after sealing a Regeneron partnership, a sequencing that is less coincidence and more investor relations strategy. The "undruggable" biotech is now gunning to be the 12th drug developer to go public this year, signaling that the IPO window is open enough to tempt even well-funded private companies.
Reality 55Hype 72 -
Quintuple Receptor Agonist Corrects Obesity and Diabetes in Mice
A single molecule hitting five metabolic targets at once — GLP-1R, GIPR, and all three PPAR subtypes — has reversed obesity and diabetes in mice, pushing the polypharmacology playbook well past semaglutide's dual-receptor ceiling.
Reality 55Hype 65 -
Ebola Bundibugyo Drug Trials Poised to Launch in DRC and Uganda
For the first time during an active Ebola Bundibugyo outbreak, clinical trials for targeted treatments are reportedly ready to deploy — closing a gap that has left this strain clinically unaddressed for years.
Reality 65Hype 55 -
Cas12a2 CRISPR Variant Destroys Targeted Cells, Including Cancer
A lesser-known CRISPR protein, Cas12a2, doesn't just edit DNA — it kills the entire cell on command. That's a fundamentally different weapon against cancer than anything currently in the clinic.
Reality 55Hype 72 -
UT Austin's Retron System Edits Multiple Disease Mutations Simultaneously
CRISPR's biggest blind spot has been patients with complex, multi-mutation disorders — a new retron-based system from UT Austin just closed that gap, correcting large defective DNA regions in a single pass.
Reality 62Hype 68 -
Researchers Standardize CRISPR Into a Plug-and-Play Genome Engineering Platform
CRISPR's biggest bottleneck was never the science — it was the setup. A new platform strips out the bespoke complexity and turns genome editing into something closer to an off-the-shelf reagent kit.
Reality 45Hype 72 -
Gene Editing Measurement Tools Become the New Bottleneck
CRISPR and its cousins can edit genomes with increasing precision — but without reliable efficiency metrics, "it worked" remains a guess. The measurement layer is quietly becoming the rate-limiting step in translating gene editing from lab curiosity to clinical product.
Reality 72Hype 35 -
Gene Editing Review Maps DNA vs. RNA Therapy Trade-offs
Fixing the genome permanently is no longer the only option — RNA editing can now rewrite disease instructions temporarily, and that reversibility is quietly reshaping which patients and conditions are worth targeting first.
Reality 72Hype 28 -
CRISPR Gene Editing Research Advances Genome Engineering Capabilities
CRISPR tooling is no longer a single instrument — it's becoming a modular platform, and the gap between lab discovery and clinical consequence is closing faster than most biotech timelines assumed.
Reality 78Hype 25